Nurexone Biologic Inc

Chart & performance

D1W1MN

P/E

—

P/S

—

EPS

Div yield, %

—

Shrs. gr., 5y

—

Rev. gr., 5y

Revenues

Net income

CFO

Notes

No notes on this company yet

Write a private note on this company, for your eyes only

Add note

Profile

NurExone Biologic Inc., a pharmaceutical technology company, develops a platform for biologically guided exosome-based therapies for the treatment of central nervous system injuries. Its lead product, ExoPTEN, has demonstrated strong preclinical data supporting clinical potential in treating acute spinal cord and optic nerve injury. The company was founded on June 27, 2011 and is headquartered in Toronto, Canada.

Key people

John Arnold

Chief Financial Officer, Corporate Secretary, Director · since 2016

Peter Reg Andrews

Director · since 2011

John-Peter Bradford

Director · since 2019

James A. Richardson

Chairman of the Board, Chief Executive Officer · since 2016

URL

https://nurexone.com/

IPO date

May 08, 2012

Employees

Domiciled in

Incorporated in

Legal address

29, 10015 - 103 Avenue NW
Edmonton, AB T5J 0H1
CA

Headquarters

22 Coulson Ave
Toronto, ON M4V 1Y5
CA

Valuation

No data to show